| Portfolio | Target | Formulation/Prototype | Cancer Indication | Stage |
|---|---|---|---|---|
| ARB-101 | CDH17 | Humanized IgG1, k | Major GI cancers | Nonclinical safety and CMC |
| ARB-201 | CDH17/CD3 | Humanized bi-specific IgG2, k | Stomach and metastatic colon cancer | Nonclinical safety and CMC |
| ARB-301 | CDH17/TROP2/tEGFR | Dual Pro-CAR vector | mCRC liver metastasis and PDAC | Pre-IND |
| Validated target | GPC3/CD3 | bi-MAB | HCC and Lung cancer | Preclinical |
| Validated target | CDH17/TROP2 | Bi-mAb | Colon and Gastric Cancers | Preclinical |
| Validated target | TIM3 | Monoclonal | CPI to reverse tumor immune suppression | Preclinical |
| Disruptive CAR/TCR-T | TAA/CPI | Immune cell therapy | Solid tumors | Preclinical |
| Disruptive CAR/TCR-T | PARK/TRIP | Immune cell therapy | Metastatic solid tumors | Discovery and POC |